Table 3: Women’s Benefit in RCTs Dedicated to HF for SGLT2is.

Trial	Primary Endpoint	CV Death	HF Events	Total HHF and CV Death	Total HHF	All-cause Mortality
Chronic HFrEF
DAPA-HF	CV death + first HHF + urgent visits for WHF HR 0.74; 95% CI [0.65-0.85] p=0.00001 RRR 26%	HR 0.82; 95% CI [0.69–0.98]; p=0.029 RRR 18%	First HHF and urgent visits for WHF HR 0.70; 95% CI [0.59–0.83]; p=0.00003 RRR 30%	0.75; 95% CI [0.65–0.88]; p=0.0002 RRR 25%	HR 0.71; 95% CI [0.61–0.82]; p<0.01 RRR 29%	HR 0.83; 95% CI [0.71–0.97) p=0.022 RRR 17%
EMPEROR-Reduced	CV death + first HHF HR 0.75; 95% CI [0.65–0.86]; p<0.001 RRR 25%	HR 0.92; 95% CI [0.75–1.12]; p=not significant RRR 8%	First HHF HR 0.69; 95% CI [0.59–0.81]; p<0.001 RRR 31%	NA	HR 0.70; 95% CI [0.58–0.85]; p<0.01 RRR 30%	HR 0.92; 95% CI [0.77–1.10]; p=not significant RRR 8%
Acute HF
SOLOIST-WHF	CV death + total HHF + urgent visits for WHF HR 0.67; 95% CI [0.52–0.85]; p=0.0009 RRR 33%	HR 0.84; 95% CI [0.58–1.22]; p=not significant RRR 16%	Total HHF + urgent visits for WHF HR 0.64; 95% CI [0.49–0.83]; p<0.001 RRR 36%	NA	NA	HR 0.82; 95% CI [0.59–1.14]; p=not significant RRR 18%

CV = cardiovascular; HF = heart failure, HFrEF = heart failure with reduced ejection fraction; HHF = hospitalisation for heart failure; NA = not applicable; RCT = randomised clinical trial; RRR = relative risk reduction; SGLT2i = sodium-glucose cotransporter type 2 inhibitors; WHF = worsening heart failure.